AEterna Zentaris Inc. (AEZS) stock prices updated...
 

AEterna Zentaris Inc. stock price

AEterna Zentaris Inc. latest news:


  • 08/04/2017 13:16:46

    BRIEF-David Dodd responds to claim filed by Aeterna Zentaris

    * David Dodd, former CEO of Aeterna Zentaris, responds to claim filed by Aeterna Zentaris against him & Philip Theodore‚Äč

  • 08/03/2017 11:31:38

    BRIEF-Aeterna Zentaris files claim against former CEO, former general counsel

    Aeterna Zentaris Inc(AEZS): * Aeterna Zentaris(AEZS) commences legal action against David Dodd and Philip Theodore.

  • 07/19/2017 11:28:53

    AEterna Zentaris's stock more than doubles on heavy volume after favorable FDA ruling

    Shares of AEterna Zentaris Inc. more than doubled on heavy volume in afternoon trade Wednesday, after the biotechnology company received a favorable ruling by regulators regarding its treatment for growth hormone deficiency in adults, Macrilen. Volume exploded to 38.9 million shares in recent trade, compared with the full-day average of about 260,000 shares. The company said late Tuesday that the Food and Drug Administration accepted the new drug application (NDA) seeking approval of Macrilen as a "complete response." The FDA granted a Prescription Drug User Fee Act (PDUFA) date of Dec. 30. "We remain confident that the FDA will approve our NDA and, therefore, we are moving forward with our preparations to launch the product in the first quarter of 2018," said Chief Executive David Dodd. The stock has still lost 30% year to date, while the iShares Nasdaq Biotechnology ETF has climbed 20% and the S&P 500 has gained 10%. The FDA had issued a "complete response letter" (CRL) on Nov. 5, 2014 saying it couldn't approve the NDA in its present form because the clinical trial didn't by itself support the indication. The stock closed at a split-adjusted $129.00 the day before the CRL was announced.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • More trends:

    Aethlon Medical, Inc.AEMD | Affimed N.V.AFMD | Affymetrix, Inc.AFFX | Agenus Inc.AGEN | Agile Therapeutics, Inc.AGRX | Agilysys, Inc.AGYS | Agios Pharmaceuticals, Inc.AGIO | AgroFresh Solutions, Inc.AGFS | AgroFresh Solutions, Inc.AGFSW | Aimmune Therapeutics, Inc.AIMT |